Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological

Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. - Abstract - Europe PMC

Molecules, Free Full-Text

WO2017163128A2 - Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders - Google Patents

Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann–Pick C1 mutant cell via lysosome-associated membrane protein 1

Fine-tuned cholesterol solubilizer, mono-6-O-α-D-maltosyl-γ-cyclodextrin, ameliorates experimental Niemann–Pick disease type C without hearing loss - ScienceDirect

Differential mode of cholesterol inclusion with 2‐hydroxypropyl‐cyclodextrins increases safety margin in treatment of Niemann‐Pick disease type C - Yamada - 2021 - British Journal of Pharmacology - Wiley Online Library

PDF) Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial

Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial - The Lancet

Sci. Pharm., Free Full-Text

Pharmaceutics, Free Full-Text

Biomolecules, Free Full-Text